chronic hepatitis D
Hepatology · 2024–2025
3decisions
1medicine
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bulevirtide Treatment of chronic hepatitis D (CHD) in patients with detectable hepatitis D virus (HDV) RNA and elevated alanine transaminase (ALT) levels, with compensated… | Jul 2025 | Recommended with restriction | input received Hepatitis Australia · Liver Foundation |
| bulevirtide Treatment of chronic hepatitis D infection (CHD) in patients with detectable hepatitis D virus (HDV) RNA and elevated alanine transaminase (ALT) levels,… | Mar 2025 | Recommended with restriction | input received Hepatitis Australia · Liver Foundation |
| bulevirtide Treatment of chronic hepatitis D (CHD) in adult patients positive for hepatitis D virus (HDV) RNA as detected by PCR. | Mar 2024 | Not recommended | input received |
Who spoke
Hepatitis Australia · Liver Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.